CD4 immunoadhesin

CD4 immunoadhesin is a recombinant fusion protein consisting of a combination of CD4 and the fragment crystallizable region. It belongs to the antibody (Ig) gene family. CD4 is a surface receptor for human immunodeficiency virus (HIV). The properties of the protein means that it has potential to be used in AIDS therapy As of 2017. One of the most relevant of these possibilities is its ability to cross the placenta.^[1]

External links

↑ Chamow, S. M.; Duliege, A. M.; Ammann, A.; Kahn, J. O.; Allen, J. D.; Eichberg, J. W.; Byrn, R. A.; Capon, D. J.; Ward, R. H.; Ashkenazi, A. (1992). "CD4 immunoadhesins in anti-HIV therapy: new developments". International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement. 7: 69–72. ISSN 0898-6924. PMID 1428410.

CD4+Immunoadhesins at the US National Library of Medicine Medical Subject Headings (MeSH)
Fletcher CV; DeVille JG; Samson PM; et al. (2007). "Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children". J. Allergy Clin. Immunol. 119 (3): 747–50. doi:10.1016/j.jaci.2006.10.045. PMC 1910693. PMID 17336619.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Chamow, S. M.; Duliege, A. M.; Ammann, A.; Kahn, J. O.; Allen, J. D.; Eichberg, J. W.; Byrn, R. A.; Capon, D. J.; Ward, R. H.; Ashkenazi, A. (1992). "CD4 immunoadhesins in anti-HIV therapy: new developments". International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement. 7: 69–72. ISSN 0898-6924. PMID 1428410.